Olaratumab for the treatment of soft-tissue sarcoma. (October 2017)

• Record Type: Journal Article
• Authors: Pender, Alexandra; Jones, Robin L
• Is Part Of: Future oncology. Volume 13:Number 24(2017)
• Page Start: 2151
• Page End: 2157
• Publication Date: 2017-10
• Subjects: olaratumab -- PDGFR-α -- sarcomas; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon-2017-0210
• Languages: English
• ISSNs: 1479-6694

Abstract

The outcome for patients with unresectable/metastatic soft tissue sarcoma remains poor with few treatment options. In the first line setting, a number of randomized trials have shown no difference in overall survival between combination anthracycline schedules and single agent doxorubicin. A Phase Ib/randomized Phase II trial of doxorubicin with or without the monoclonal antibody to PDGFR-α, olaratumab, demonstrated a significant difference in median overall survival in favor of the olaratumab arm. The results of this trial led to approval of olaratumab in combination with doxorubicin in adult anthracycline-naive unresectable soft tissue sarcoma. In this review, we describe some of the preclinical and early clinical data of olaratumab in sarcomas, the Phase Ib/II trial and ongoing trials with olaratumab in sarcomas.